Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study.
暂无分享,去创建一个
Min Hyung Kim | S. Han | D. Yong | Sun Bean Kim | J. Ahn | S. Jeong | N. Ku | J. Choi | Y. Song | J. Kim | J. Song | H. Ann | Y. Jeon | Heun Choi | Jung Ho Kim | Kyungwon Lee | Jae Kyung Kim | J. Song | J. Song
[1] A. Apisarnthanarak,et al. Risk Factors and Outcomes of Carbapenem-resistant Acinetobacter baumannii Bacteremia in Neonatal Intensive Care Unit: A Case-case-control Study , 2013, The Pediatric infectious disease journal.
[2] B. Betsch,et al. Transmission Dynamics of Extended-Spectrum β-lactamase–Producing Enterobacteriaceae in the Tertiary Care Hospital and the Household Setting , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Yun Xia,et al. Characterization of Carbapenemase Genes in Enterobacteriaceae Species Exhibiting Decreased Susceptibility to Carbapenems in a University Hospital in Chongqing, China , 2012, Annals of laboratory medicine.
[4] P. Nordmann,et al. Carbapenem resistance in Enterobacteriaceae: here is the storm! , 2012, Trends in molecular medicine.
[5] Tsu‐Lan Wu,et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[6] K. Ko,et al. Bloodstream Infections and Clinical Significance of Healthcare-associated Bacteremia: A Multicenter Surveillance Study in Korean Hospitals , 2010, Journal of Korean medical science.
[7] P. Della‐Latta,et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. , 2010, Diagnostic microbiology and infectious disease.
[8] Ronald N. Jones,et al. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). , 2009, Diagnostic microbiology and infectious disease.
[9] D. Nicolau,et al. Risk Factors and Outcomes Associated with Isolation of Meropenem High-Level-Resistant Pseudomonas aeruginosa , 2009, Infection Control & Hospital Epidemiology.
[10] Yehuda Carmeli,et al. Carbapenem-resistant Enterobacteriaceae: a potential threat. , 2008, JAMA.
[11] J. Campos,et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. , 2008, International journal of antimicrobial agents.
[12] A. Hidrón,et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 , 2008, Infection Control & Hospital Epidemiology.
[13] N. Woodford,et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. , 2008, International journal of antimicrobial agents.
[14] A. Vatopoulos. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[15] Fotini C Chelvatzoglou,et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. , 2007, The Journal of antimicrobial chemotherapy.
[16] K. Bush,et al. Carbapenemases: the Versatile β-Lactamases , 2007, Clinical Microbiology Reviews.
[17] S. Choi,et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. , 2006, Diagnostic microbiology and infectious disease.
[18] T. Gootz,et al. High-Level Carbapenem Resistance in a Klebsiella pneumoniae Clinical Isolate Is Due to the Combination of blaACT-1 β-Lactamase Production, Porin OmpK35/36 Insertional Inactivation, and Down-Regulation of the Phosphate Transport Porin PhoE , 2006, Antimicrobial Agents and Chemotherapy.
[19] Y. Carmeli,et al. Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant Escherichia coli Clones in Israel , 2006, Antimicrobial Agents and Chemotherapy.
[20] W. Bilker,et al. Imipenem Resistance Among Pseudomonas aeruginosa Isolates Risk Factors for Infection and Impact of Resistance on Clinical and Economic Outcomes , 2006, Infection Control & Hospital Epidemiology.
[21] S. Choi,et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. , 2005, Microbial drug resistance.
[22] Baha Abdalhamid,et al. Escherichia coli: development of carbapenem resistance during therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] P. Nordmann,et al. In Vivo Acquisition of High-Level Resistance to Imipenem in Escherichia coli , 2004, Journal of Clinical Microbiology.
[24] D. Schwartz,et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] A. Harris. Control group selection is an important but neglected issue in studies of antibiotic resistance. , 2000, Annals of internal medicine.
[26] G. French,et al. Carbapenem Resistance in Escherichia coli Associated with Plasmid-Determined CMY-4 β-Lactamase Production and Loss of an Outer Membrane Protein , 1999, Antimicrobial Agents and Chemotherapy.
[27] Suvarna Sk,et al. Morphological changes in Pseudomonas aeruginosa secondary to ciprofloxacin. , 1997 .
[28] G. Aubert,et al. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. , 1992, The Journal of antimicrobial chemotherapy.
[29] A. Kampen,et al. A matched case-control study of 13 patients , 2009 .
[30] Iraida E. Robledo,et al. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. , 2009, MMWR. Morbidity and mortality weekly report.
[31] S. Suvarna,et al. Morphological changes in Pseudomonas aeruginosa secondary to ciprofloxacin. , 1997, Histopathology.